| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
|---|
|
| | | IP | CI | | Ebvallo | | PR | PR | k.A. | | | Pierre Fabre Pharma SA | A | FB | | G |  |
| | | IP | CI | | Imodium ‐ I - T | 20 Capsule(s) | 3.87 | 6.85 | 20 % | | Capsules: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D / SL / SO | FB | | G | |
| | | IP | CI | | Imodium - T | 60 Capsule(s) | 9.40 | 26.60 | 20 % | | Capsules: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | B / SL / SO | FB | | G | |
| L | | IP | CI | | Microlax | 4 x 5 ml | 4.15 | 7.65 | 10 % | | Enema: 3 Active Agents | JNTL Consumer Health II
(Switzerland) GmbH | D / SL | FB | | G | |
| L | | IP | CI | | Microlax | 12 x 5 ml | 12.45 | 23.00 | 10 % | | Enema: 3 Active Agents | JNTL Consumer Health II
(Switzerland) GmbH | D / SL / LPPV | FB | | G | |
| L | | IP | CI | | Microlax | 50 x 5 ml | 51.88 | 95.80 | 10 % | | Enema: 3 Active Agents | JNTL Consumer Health II
(Switzerland) GmbH | D / SL / LPPV | FB | | G | |
| L | | IP | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10 % | | Concentrate for infusion: Bevacizumabum 100mg / 4ml | iQone Healthcare
Switzerland SA | A / SL | FB | | G | |
| L | | IP | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10 % | | Concentrate for infusion: Bevacizumabum 400mg / 16ml | iQone Healthcare
Switzerland SA | A / SL | FB | | G | |
| L | | IP | | PP | Herceptin subkutan
600mg/5ml | | 1484.04 | 1630.40 | 10 % | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma
(Schweiz) AG | A / SL | FB | | G | |
| L | | IP | | | Ogivri 150 mg | | 456.84 | 513.25 | 10 % | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / SL | FB | | G | |
| | | IP | CI | | Bilaxten 6 mg / ml | 5 ml | PR | PR | k.A. | | Eye drops: Bilastinum 6 mg/ml | A. Menarini GmbH | B | FB | | G | |
| | | IP | CI | | Imodium lingual akut | 10 | PR | PR | k.A. | | Melting tablets: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D | FB | | G | |
| | | IP | CI | | Imodium lingual akut | 12 | PR | PR | k.A. | | Melting tablets: Loperamidi Hydrochloridum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D | FB | | G | |
| | | IP | CI | | Nicorette Microtab
Original-Aroma | 100 Tablet(s) | PR | PR | k.A. | | Sublingual tablets: Nicotinum 2 mg | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | CI | | Regaine 5 % | 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | CI | | Regaine 5 % | 3 x 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | | | Mylotarg 5 mg | | PR | PR | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G | |
|
| L | | IP | | V/S | Varivax | Durchstechflasche(n) | 42.39 | 62.50 | 10 % | | Injection suspension: Virus Varicellae Vivus (Stamm Oka) 1350 U | MSD Merck Sharp &
Dohme AG | B / SL | FB | | G | |
| L | | IP | | V/S | Varilrix | | 41.30 | 61.35 | 10 % | | Lyophilisate and solvent: Virus Varicellae Vivus (Stamm Oka) 10 U | GlaxoSmithKline AG | B / SL | FB | | G | |
